


YMS-16
71



St. James Community Hospital, Inc.

Log *July-3-15*
Remitter
Check No. *65432-95564*
Amount *\$120* - *\$120*
Fee Category *7C* - *Refunded*
Type of Fee *And.*
Date Check Rec'd. *8/4/86*
Date Completed *8/1/86*
By: *Russier*



Jul, 10, 1986

United States Nuclear Regulatory
Commission Region IV
Attn: Mr. J. E. Whitten
Nuclear Materials Safety Section
611 Ryan Plaza Drive
Arlington, Texas 76011

Control No. 461064

Dear Mr. Whitten:

St. James Community Hospital, Inc. submits the NRC license for Dr. Eugene Hughes. Dr. Hughes has been licensed for Group VI materials on NRC License number 24-01143-06 (copy enclosed) and for P-32 for treating malignant effusion. It is the hospital's request that Dr. Hughes be licensed for Group VI materials, including P-32, on our NRC Medical Isotope License.

The extremity dose for the individuals working with sealed sources will be monitored by using finger badges supplied by our whole body film badge supplier - Siemens. The Group VI materials will be transported to the patient's room using commercially available lead pigs designed for transporting Group VI materials.

Source accountability will be maintained by a written log. The log shall contain and identify sources (5mg, 10mg, 15mg, etc.) on separate pages. As the sources are used, the page that is identified for that particular source will contain a notation identifying the patient and his/her room number, the number of sources of that type used, the number remaining, the date the sources were removed from storage, the date the sources were returned, the number of sources upon return, the initials of the person removing the sources and the initials of the individual returning the sources. In addition, a careful map will allow you to compare the type of source for each location, so you may compare the map with the current source counting. In this manner, any missing sources will be readily identifiable.

The individual designated for source accountability will be the Chief Technologist for Radiation Therapy. It will be his/her responsibility to ensure that the sources that have been requested, used and returned will be appropriately accounted for from the start of the procedure to its completion.

The inventory for materials used for brachytherapy purposes will be placed in the source log. All materials, as they are received from the manufacturer, will be

461064

United States Nuclear Regulatory Commission

July 10, 1986

Page 2

entered into the log and identified either with a patient or with a location within the department. Such a log (example enclosed) will contain a column, identifying the number of sources, their location and their serial numbers. The sources will be inventoried on a monthly basis.

The NRC guideline for room surveys will be followed as found in Appendix L of Regulation Guide 10.8. Upon initial application of the Group VI materials, a survey will be done at bedside at the foot of the bed, along the bedside shield and outside the room to determine that the radiation dose levels are within the NRC guidelines. Following treatment and after a source removal, a survey will be done to ensure that no radioactive material has remained in the room.

Appendix L for nursing instructions will be followed for informing the nurses about the risk and the precautions they should take about the radioactive materials. In addition, an annual lecture will be given to the staff ensuring they have the appropriate respect and caution while working around radioactive material.

If there are any further questions, please do not hesitate to contact me.

Sincerely,

Richard T. Moore

Richard Moore,
Senior Vice President

Enclosures (2)

RM/1a



MATERIALS LICENSE
SUPPLEMENTARY SHEET

License number

24-01143-06

Docket or Reference number

030-09784

Amendment No. 28

Lester E. Cox Medical Center
1423 N. Jefferson Avenue
Springfield, MO 65802

In accordance with letter dated March 5, 1985, License Number 24-01143-06 is amended as follows:

Condition 12. is amended to read:

12. Licensed material listed in Item 6 above is authorized for use by, or under the supervision of, the following individual(s) for the materials and uses indicated:

L. D. Litton, M.D.

Groups I, II, III, IV, V and VI
Xenon-133
In vitro studies

L. R. Brent, M.D.

Groups I, II, III, IV, V and VI
Xenon-133
In vitro studies

P. S. Quinn, M.D.

Groups I, II and III
Xenon-133
In vitro studies

D. E. Nelson, M.D.

Groups I, II and III
Xenon-133
In vitro studies

P. Schoenfelder, M.D.

Groups I, II and III
Xenon-133
In vitro studies

H. C. Krahn, M.D.

Groups I, II and III
Xenon-133
Phosphorus-32 for treatment of
polycythemia vera, leukemia and
bone metastases
Iodine-131 for treatment of
hyperthyroidism, cardiac
dysfunction and thyroid carcinoma

E. F. Hughes, Jr., M.D.

Group VI

For the U.S. Nuclear Regulatory Commission

Date APR 09 1985

By Belinda B. Matson
Materials Licensing Section, Region III

8504240328

1p.

END

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License number 24-01143-06

Docket or Reference number 030-09784

Amendment No. 31

E. F. Hughes, Jr., M.D.

Group VI
Colloidal Phosphorus-32 for
intercavitary treatment of
malignant effusions

Joseph Drewry Rogers, M.D.

Group VI

Robert Love McLaurin, Jr., M.D.

Group VI



For the U.S. Nuclear Regulatory Commission

Date NOV 14 1985

Original Signed
By George M. McCann
Materials Licensing Section, Region III

8512020149

1p

COPY